Yeah that’s all correct. It’s particularly notable because the study was a third line treatment. These patients had already progressed after taking a platinum b

Yeah that’s all correct. It’s particularly notable because the study was a third line treatment. These patients had already progressed after taking a platinum based chemotherapy, which is a standard first treatment, and they also progressed after taking a PD-L1 immunotherapy. So these patients had very advanced and difficult to treat cancer. This represents a real improvement for them as they probably didn't have many options left outside very invasive surgeries or lots of radiation to the head and neck. Also the treatment targets two cancer genes at the same time. The first is EGFR, which is a very well known therapeutic target. The second is LGR5, and I’m not as familiar with that one, but I think it might be a novel target for cancer. So that's important in that more drugs might target this gene or combinations of LGR5 and others and they might be more effective than this first effort.